First Time Loading...

BioXcel Therapeutics Inc
NASDAQ:BTAI

Watchlist Manager
BioXcel Therapeutics Inc Logo
BioXcel Therapeutics Inc
NASDAQ:BTAI
Watchlist
Price: 2.82 USD -2.08% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

BTAI's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. [ Read More ]

The intrinsic value of one BTAI stock under the Base Case scenario is 6.66 USD. Compared to the current market price of 2.82 USD, BioXcel Therapeutics Inc is Undervalued by 58%.

Key Points:
BTAI Intrinsic Value
Base Case
6.66 USD
Undervaluation 58%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
BioXcel Therapeutics Inc

Backtest BTAI Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BTAI stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of BioXcel Therapeutics Inc's business.

What risks and challenges
does BioXcel Therapeutics Inc face in the near future?

Summarize the latest earnings report
of BioXcel Therapeutics Inc.

Provide P/E
for BioXcel Therapeutics Inc and its competitors.

Financials

Balance Sheet Decomposition
BioXcel Therapeutics Inc

Current Assets 98.7m
Cash & Short-Term Investments 90m
Receivables 700k
Other Current Assets 8m
Non-Current Assets 1.7m
PP&E 1.6m
Other Non-Current Assets 100k
Current Liabilities 39.4m
Accounts Payable 10.7m
Accrued Liabilities 27.4m
Other Current Liabilities 1.3m
Non-Current Liabilities 101.7m
Long-Term Debt 99.1m
Other Non-Current Liabilities 2.6m
Efficiency

Earnings Waterfall
BioXcel Therapeutics Inc

Revenue
1.4m USD
Cost of Revenue
-1.3m USD
Gross Profit
120k USD
Operating Expenses
-167.7m USD
Operating Income
-167.6m USD
Other Expenses
-11.4m USD
Net Income
-179.1m USD

Free Cash Flow Analysis
BioXcel Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

BTAI Profitability Score
Profitability Due Diligence

BioXcel Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Positive Gross Profit
Declining ROE
23/100
Profitability
Score

BioXcel Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

BTAI Solvency Score
Solvency Due Diligence

BioXcel Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
50/100
Solvency
Score

BioXcel Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BTAI Price Targets Summary
BioXcel Therapeutics Inc

Wall Street analysts forecast BTAI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BTAI is 13.52 USD with a low forecast of 4.04 USD and a high forecast of 26.25 USD.

Lowest
Price Target
4.04 USD
43% Upside
Average
Price Target
13.52 USD
379% Upside
Highest
Price Target
26.25 USD
831% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

BTAI Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BTAI Price
BioXcel Therapeutics Inc

1M 1M
-11%
6M 6M
+11%
1Y 1Y
-84%
3Y 3Y
-93%
5Y 5Y
-71%
10Y 10Y
-74%
Annual Price Range
2.82
52w Low
1.95
52w High
28.58
Price Metrics
Average Annual Return 64.85%
Standard Deviation of Annual Returns 151.17%
Max Drawdown -97%
Shares Statistics
Market Capitalization 82.6m USD
Shares Outstanding 30 381 900
Percentage of Shares Shorted 45.98%

BTAI Return Decomposition
Main factors of price return

What is price return decomposition?

BTAI News

Last Important Events
BioXcel Therapeutics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
BioXcel Therapeutics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

BioXcel Therapeutics Inc Logo
BioXcel Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

82.6m USD

Dividend Yield

0%

Description

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The company is headquartered in New Haven, Connecticut and currently employs 89 full-time employees. The company went IPO on 2018-03-08. The company is focused on utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. Its two advanced clinical development programs are BXCL501, which is an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, which is an investigational orally administered systemic innate immune activator for the treatment of castration resistant prostate cancer and advanced solid tumors that are refractory or treatment nave to checkpoint inhibitors. The company is conducting a Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA (pembrolizumab) for metastatic castration-resistant prostate cancer (mCRPC), in patients with adenocarcinoma and in patients with the aggressive variant small-cell neuroendocrine carcinoma.

Contact

CONNECTICUT
New Haven
555 Long Wharf Dr
+12036438060.0
http://www.bioxceltherapeutics.com/

IPO

2018-03-08

Employees

89

Officers

Founder, CEO, President, & Director
Dr. Vimal D. Mehta Ph.D.
Senior VP, Chief Legal Officer & Corporate Secretary
Mr. Javier Rodriguez
Senior VP & Chief Commercial Officer
Mr. Matthew Wiley
Senior VP & CFO
Mr. Richard I. Steinhart MBA
Senior VP & Chief Scientific Officer
Dr. Frank D. Yocca Ph.D.
Executive VP, Chief of Product Development & Medical Officer
Dr. Vincent J. O'Neill B.Sc., M.D., M.R.C.P.
Show More
Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs
Dr. Chetan D. Lathia Ph.D.
Chief Medical Officer - Neuroscience
Dr. Robert Risinger M.D.
Vice President of Commercial Operations & Launch Planning
Mr. Robert Scala
Senior Director of Neuroscience & Artificial intelligence
Dr. Friso Postma
Show Less

See Also

Discover More
What is the Intrinsic Value of one BTAI stock?

The intrinsic value of one BTAI stock under the Base Case scenario is 6.66 USD.

Is BTAI stock undervalued or overvalued?

Compared to the current market price of 2.82 USD, BioXcel Therapeutics Inc is Undervalued by 58%.